The company mission is to empower clinicians and physicians everywhere with the genetic data about their patient; enabling them to make informed therapy decisions faster. The company is developing a patent pending integrated automated bench-top NGS genetic testing lab to enable hospitals and medical centres around the world to carry on tests on site close to the Point of Need. The target sectors we are aiming for include pathogen identification, Anti Microbial Resistance (AMR) testing, NIPT, new born screening, oncology, predictive genetics, infectious disease screening and we plan to target other applications that would benefit from onsite genetics and fast turn around times and significantly lower costs. We are inaugural members of the Wyss Institute at Harvard Diagnostic Accelerator Industry Particpants Programme (IPP).